Survival Time and Immunological Recovery of AIDS Patients Under Antiretroviral Treatment: a Case Study at Felege Hiwot Referal Hospital, Bahir-Dar, Ethiopia.

dc.contributor.advisorWencheko, Eshetu(Professer)
dc.contributor.authorEshetu, Bezalem
dc.date.accessioned2018-06-25T09:21:57Z
dc.date.accessioned2023-11-09T14:29:44Z
dc.date.available2018-06-25T09:21:57Z
dc.date.available2023-11-09T14:29:44Z
dc.date.issued2014-06
dc.description.abstractAntiretroviral Treatment (ART), although not a cure, can help people from becoming ill for many years and this has improved the survival and recovery time of HIV patients. In 2011 a number of 249,174 adults were on ART in Ethiopia. Although ART treatment has decreased HIV associated mortality and morbidity, a number of patients still die after the start of ART. The purpose of this study was to identify factors affecting the survival time and time to immunological recovery of HIV/AIDS patients under ART treatment. A sample of 387 patients was taken from patients’ records at Bahir-Dar Felege-Hiwot Referral Hospital from June 2006 to August 2013. Kaplan-Meier estimation method and Cox proportional hazard model were applied to describe and analyze the data. Females, baseline CD4 count >200cell/μl, TB-negative, total lymphocyte count ≥1200 cell/mm3 and baseline weight ≥45kg, no regimen change, good adherence to treatment, WHO stage I, working functional status and negative-anemia were identified with longer survival time and shorter recovery time at 5% of significance level. Patients having no risk behaviors lived longer. Based on the Cox regression model results the adjusted HRs were as follows: high CD4 count (aHR=0.99), negative-anemia patients (aHR=0.27), good adherence to treatment (aHR=0.10), fair adherence to treatment (aHR=0.47), male gender (aHR=1.81), TB-positive (aHR=3.58), bedridden functional status (aHR=5.07), ambulatory functional status (aHR=1.30). The adjusted HRs for recovery time were as follows: patients with high CD4 count (aHR=1.02), high weight (≥45kg.) (aHR=1.03), WHO stage I (aHR=1.88), WHO stage II (aHR=1.67) and negative-anemia (aHR=1.34) had shorter time to immunological recovery at 5% level of significance. Male gender (aHR =0.73), old age (aHR=0.98), total lymphocyte count <1200 (aHR=0.77) and regimen change (aHR=0.688) were significantly associated with extended time to immunological recovery at 5% level.en_US
dc.identifier.urihttp://10.90.10.223:4000/handle/123456789/3129
dc.language.isoenen_US
dc.publisherAddis Abeba universityen_US
dc.titleSurvival Time and Immunological Recovery of AIDS Patients Under Antiretroviral Treatment: a Case Study at Felege Hiwot Referal Hospital, Bahir-Dar, Ethiopia.en_US
dc.typeThesisen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Bezalem Eshetu.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:

Collections